US 12,385,926 B2
MMP-8 as a marker for identifying infectious disease
Jesus F. Bermejo Martin, Soria (ES); Eduardo Tamayo Gomez, Soria (ES); David Andaluz Ojeda, Soria (ES); Lydia Blanco Peris, Soria (ES); Alicia Ortega Andres, Soria (ES); and Raquel Almansa Mora, Soria (ES)
Assigned to B.R.A.H.M.S GmbH, Hennigsdorf (DE); and Fundacion Instituto de Estudios de Ciencias de la Salud de Castilla y Leon, Soria (ES)
Appl. No. 16/617,622
Filed by B.R.A.H.M.S GmbH, Hennigsdorf (DE); and Fundacion Instituto de Estudios de Ciencias de la Salud de Castilla y Leon, Soria (ES)
PCT Filed May 31, 2018, PCT No. PCT/EP2018/064363
§ 371(c)(1), (2) Date Nov. 27, 2019,
PCT Pub. No. WO2018/220129, PCT Pub. Date Dec. 6, 2018.
Claims priority of application No. 17173724 (EP), filed on May 31, 2017.
Prior Publication US 2020/0225248 A1, Jul. 16, 2020
Int. Cl. C12Q 1/6883 (2018.01); A61K 31/43 (2006.01); A61K 31/431 (2006.01); A61K 31/7048 (2006.01); A61K 35/00 (2006.01); A61K 36/00 (2006.01); G01N 33/68 (2006.01); C07G 11/00 (2006.01)
CPC G01N 33/6893 (2013.01) [C12Q 1/6883 (2013.01); G01N 2333/988 (2013.01); G01N 2800/102 (2013.01); G01N 2800/26 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01)] 12 Claims
 
1. A method for diagnosis and treatment of bacterial sepsis, severe sepsis and/or septic shock in a subject, wherein said method comprises:
providing a sample from said subject wherein the subject has symptoms of a systemic inflammatory response syndrome (SIRS) or dyspnea;
measuring the metalloprotease-8 (MMP-8) in the sample from said subject,
wherein when the level of MMP-8 in the sample of said subject is above a reference level, threshold value and/or a population average corresponding to MMP-8 level in subjects with a systemic inflammatory response syndrome (SIRS) or dyspnea without an infection, the said level of MMP-8 being indicative of the presence of a bacterial sepsis, severe sepsis, and/or septic shock in said subject, the method comprises administering to said subject an effective amount of an antibiotic.